2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Gene Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric, Animal Model
PAPER

3185 Safe-TBD: A multicenter retrospective study of bone marrow surveillance and myeloid neoplasms in telomere biology disorders

Aaron N. Cheng, MD, Amar Zaidan2, Madison Kingsbury, BS3, Brittany Borden, MD4, Luiz Fernando Bazzo Catto, MD, PhD5, Victoria Heigh, MD6, Stephanie Soewito, DO7, Fabian Fabian Beier, MD8, Luca Arcuri, MD9, Brandon Lucari, MD10, Maria Carla Giarratana, MD11, Christopher Sande, MD12, Jiayin Zheng, PhD13, Tim H. H. Brummendorf, MD14, Wei Ying Jen, BM BCh, FRCPath15, Sanam Loghavi, MD16, Amy Geddis, MD, PhD17, Sioban Keel, MD18, Marcin W Wlodarski, MD, PhD19, Carlo Dufour I, MD20, Jane Churpek, MD, MS21, Courtney DiNardo, MD, MSCE22, Alejandro Ferrer, PhD23, Mrinal M. Patnaik, MD, MBBS24, Abhishek Avinash Mangaonkar, MBBS25, Rodrigo T. Calado, MD, PhD26, Neelam Giri, MBBS, MD27, Sharon A Savage, MD28, Fernanda Gutierrez-Rodrigues, PhD29, Emma Groarke, MD30, Christopher R. Reilly, MD31, Alison A. Bertuch, MD, PhD32, Timothy S. Olson, MD, PhD33, Daria V. Babushok Jr, MD, PhD34
1 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 National Institutes of Health, Bethesda, Maryland, United States
6 Columbia University, New York City, New York, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 RWTH Aachen University, Aachen, Germany
9 IRCCS Istituto Giannina Gaslini, Genoa, Italy
10 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Cancer and Hematology Centers, Houston, Texas, United States
11 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
12 Seattle Children’s Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
13 University of Pennsylvania Perelman School of Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
14 RWTH Aachen University, Aachen, Germany
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Seattle Children’s Hospital, Seattle, Washington, United States
18 University of Washington, Seattle, Washington, United States
19 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
20 IRCCS Istituto Giannina Gaslini, Genoa, Italy
21 University of Wisconsin-Madison, Madison, Wisconsin, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
27 National Institutes of Health, Bethesda, Maryland, United States
28 National Institutes of Health, Bethesda, Maryland, United States
29 National Institutes of Health, Bethesda, Maryland, United States
30 National Institutes of Health, Bethesda, Maryland, United States
31 Dana Farber Cancer Institute, Boston, Massachusetts, United States
32 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Cancer and Hematology Centers, Houston, Texas, United States
33 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
34 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Telomere biology disorders (TBDs) are inherited telomere maintenance disorders associated with bone marrow failure (BMF) and increased risk of myeloid neoplasms (MNs). Although annual bone marrow (BM) surveillance has historically been recommended, TBDs have variable MN risk and extrahematopoietic manifestations, underscoring the need for risk-adapted surveillance. We analyzed a large retrospective TBD cohort to assess how MN risk varies across age, diagnostic yield of BM surveillance, and outcomes.

We examined 719 individuals from 12 institutions, diagnosed using telomere length (TL), genetic testing, and clinical criteria. Lymphocyte TL was <1st percentile in 384 (53.4%), 1st–10th in 196 (27.3%), >10th in 14 (1.9%), and unknown in 125 (17.4%). Germline TBD variants included TERT (30.0%), RTEL1 (15.9%), TERC (14.7%), DKC1 (3.3%), and PARN (3.3%); 3.5% had variants in multiple genes; 22.4% had no identified variants.

TBD was diagnosed at a median of 44 years (range <1-83), 176 as children (age ≤21 24.5%) and 543 as adults (75.5%); with a bimodal age distribution peaking at <10 and >50 years. Among those with TL <10th percentile, children had more TL <1st compared to adults (OR 4.94, p<0.001). Compared to adults, children were also more likely to have autosomal recessive/X-linked/TINF2-TBD (OR 7.62, p<0.001). Children had more BMF (OR 1.65, p=0.005) and received more hematopoietic cell transplantation (HCT; OR 3.49, p<0.001) than adults, but only 6.5% of children were transplanted for MN vs 62% of adults (OR 23.4; p<0.001).  

MNs, most commonly myelodysplastic syndrome (MDS) and acute myeloid leukemia, occurred in 90 patients (13%) [16% of adults vs 3% of children, p<0.001] at a median of 53 years (<1–73). MN was a presenting manifestation of TBD in 78/90 (87%): 59 diagnosed before and 19 concurrently with TBD diagnosis.

Time-to-event began at TBD diagnosis. “Incident MN” was defined as new MN diagnosed >3 months after TBD. Among 634 patients evaluable for incident MN, 5- and 10-year cumulative incidences of MN were 2.3% (95% CI, 0.8%–3.9%) and 4.1% (95% CI, 1.6%–6.7%), respectively, with HCT and death treated as competing events. Among 719 patients, 162 died; overall survival was 73.7% (95% CI, 69.6%–78.1%) at 5 years and 54.4% (95% CI, 47.6%–62.2%) at 10 years after TBD diagnosis.

Of evaluable patients, 344 had ≥1 BM biopsy: 255 adults (median, 1; range, 1–11) and 89 children (median, 2; range, 1–14); 288 had no biopsies. Patients with and without biopsies were similar in age (74.1% vs 72.9% adults; median, 42 vs 43 years; p=0.534), but differed clinically. Biopsied patients more often had TL <1st percentile (61.6% vs 45.1%; p<0.001), BMF/cytopenias (76.7% vs 52.8%; p<0.001), and lung disease (52.8% vs 43.7%; p=0.025), and had longer follow-up (2.94 vs 2.0 years; p<0.001).

Incident MN (all MDS) developed in 12/344 (3.5%) biopsied patients—0/89 children (0%) and 12/255 adults (4.7%) at a median 2.6 years (range, 0.4–7.4) after TBD diagnosis, versus none without biopsies (p<0.001). Clonal hematopoiesis (CH) was assessed clinically using cytogenetic abnormalities and somatic variants; panel content and sensitivity varied by institution and evolved over time. Genes disproportionately mutated in incident MN versus no MN were U2AF1 (25.0% vs 3.6%; p=0.011), SF3B1 (25.0% vs 0.9%; p<0.001), and RUNX1 (16.7% vs 0.3%; p=0.003). Among patients with MN diagnosed before or with TBD, the most common alterations were U2AF1 (17.5% vs 3.7%; p<0.001), TP53 (14.0% vs 2.6%; p<0.001), and complex cytogenetics (15.8% vs 0.3%; p<0.001), all of which were more frequent than in patients without MN.

Incident MN was most often diagnosed on biopsies prompted by changing hematologic parameters (3/38; 7.9%), vs. initial biopsies after TBD diagnosis (6/137; 4.4%; p=0.410) and routine surveillance biopsies (3/334; 0.9%%; p=0.016). Including pre-TBD and concurrent MNs, 58/452 (12.8%) evaluable initial BM biopsies diagnosed MN.

In conclusion, MN, HCT, and mortality risks in TBD vary with age at TBD diagnosis, which correlates with underlying TBD biology. More than 80% of MNs are diagnosed as the initial manifestation of TBD in mid-adulthood, limiting the utility of guideline-based annual surveillance after TBD diagnosis. Frequently concurrent MN and TBD diagnoses support a baseline BM biopsy, especially in adults. Subsequent biopsies should be guided by evolving blood counts, high-risk CH, HCT considerations, and competing extrahematopoietic risks.

Aaron N. Cheng, MD: Agios Pharmaceuticals - Consultancy (Includes expert testimony)